TRIP11
Thyroid receptor-interacting protein 11
Protein Summary
Binds the ligand binding domain of the thyroid receptor (THRB) in the presence of triiodothyronine and enhances THRB-modulated transcription. Golgi auto-antigen; probably involved in maintaining cis-Golgi structure. This gene was identified based on the interaction of its protein product with thyroid hormone receptor beta. This protein is associated with the Golgi apparatus. The N-terminal region of the protein binds Golgi membranes and the C-terminal region binds the minus ends of microtubules; thus, the protein is thought to play a role in assembly and maintenance of the Golgi ribbon structure around the centrosome. Mutations in this gene cause achondrogenesis type IA.[provided by RefSeq, Mar 2010]
- ENST00000267622
- ENSP00000267622
- ENSG00000100815
- CEV14
- ODCD
- ACG1A
- CEV14
- GMAP210
- TRIP-11
- TRIP230
- GMAP-210
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 0.91 | ||
histone modification site profile | 0.78 | ||
cellular component | 0.71 | ||
gene perturbation | 0.7 | ||
cell line | 0.67 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 48.85 (req: < 5)
Gene RIFs: 15 (req: <= 3)
Antibodies: 85 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 48.85 (req: >= 5)
Gene RIFs: 15 (req: > 3)
Antibodies: 85 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 8
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0